Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete |